437 related articles for article (PubMed ID: 32290732)
1. Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis.
Gama F; Ferreira J; Carmo J; Costa FM; Carvalho S; Carmo P; Cavaco D; Morgado FB; Adragão P; Mendes M
J Am Heart Assoc; 2020 Apr; 9(8):e015177. PubMed ID: 32290732
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
3. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
Packer M
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e007430. PubMed ID: 31159583
[No Abstract] [Full Text] [Related]
4. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
[TBL] [Abstract][Full Text] [Related]
5. Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
Schrage B; Uijl A; Benson L; Westermann D; Ståhlberg M; Stolfo D; Dahlström U; Linde C; Braunschweig F; Savarese G
Circulation; 2019 Nov; 140(19):1530-1539. PubMed ID: 31476893
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
[TBL] [Abstract][Full Text] [Related]
7. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
8. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
[TBL] [Abstract][Full Text] [Related]
9. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
Akel T; Lafferty J
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
[TBL] [Abstract][Full Text] [Related]
11. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
Stavrakis S; Asad Z; Reynolds D
J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation.
Algalarrondo V; Perault R; Bories MC; Narayanan K; Garcia R; Combes N; Perier MC; Defaye P; Sadoul N; Gras D; Klug D; Bordachar P; Fauchier L; Deharo JC; Leclercq C; Boveda S; Marijon E; Babuty D;
Arch Cardiovasc Dis; 2018 Dec; 111(12):758-765. PubMed ID: 30078651
[TBL] [Abstract][Full Text] [Related]
13. Joint Shock/Death Risk Prediction Model for Patients Considering Implantable Cardioverter-Defibrillators.
Reeder HT; Shen C; Buxton AE; Haneuse SJ; Kramer DB
Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005675. PubMed ID: 31412732
[TBL] [Abstract][Full Text] [Related]
14. Impact of Improved Left Ventricular Systolic Function on the Recurrence of Ventricular Arrhythmia in Heart Failure Patients With an Implantable Cardioverter-Defibrillator.
Kim M; Kim J; Lee JH; Hwang YM; Kim MS; Nam GB; Choi KJ; Kim JJ; Kim YH
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1191-1198. PubMed ID: 27334231
[TBL] [Abstract][Full Text] [Related]
15. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
[TBL] [Abstract][Full Text] [Related]
16. Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.
Elming MB; Hammer-Hansen S; Voges I; Nyktari E; Raja AA; Svendsen JH; Pehrson S; Signorovitch J; Køber LV; Prasad SK; Thune JJ
Circ Arrhythm Electrophysiol; 2019 Mar; 12(3):e007022. PubMed ID: 30866666
[TBL] [Abstract][Full Text] [Related]
17. Risk of Appropriate Therapy and Death Before Therapy After Implantable Cardioverter-Defibrillator Generator Replacement.
Witt CM; Waks JW; Mehta RA; Friedman PA; Kramer DB; Buxton AE; Mulpuru SK; Noseworthy PA; Hodge DO; Lushinsky EC; Mulholland MB; Cha YM; Gersh BJ; Madhavan M
Circ Arrhythm Electrophysiol; 2018 Aug; 11(8):e006155. PubMed ID: 30354311
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in heart failure patients referred for consideration of implantable cardioverter defibrillator for primary prophylaxis of sudden cardiac death: what are the risks of waiting?
Ghosh N; Mangat I; O'Donnell SS; Pinter A; Korley V; Lane C; Dorian P
Can J Cardiol; 2009 Oct; 25(10):e342-346. PubMed ID: 19812807
[TBL] [Abstract][Full Text] [Related]
19. Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification.
Cubbon RM; Witte KK; Kearney LC; Gierula J; Byrom R; Paton M; Sengupta A; Patel PA; Mn Walker A; Cairns DA; Rajwani A; Hall AS; Sapsford RJ; Kearney MT
Heart; 2016 May; 102(10):735-40. PubMed ID: 26857212
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women.
Zeitler EP; Hellkamp AS; Schulte PJ; Fonarow GC; Hernandez AF; Peterson ED; Sanders GD; Yancy CW; Al-Khatib SM
Circ Heart Fail; 2016 Jan; 9(1):e002630. PubMed ID: 26758365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
